Effects of Traditional Chinese Medicine Shensong Yangxin Capsules on Heart Rhythm and Function in Congestive Heart Failure Patients with Frequent Ventricular Premature Complexes：A Randomized, Double-blind, Multicenter Clinical Trial
Background：Pharmacological therapy for congestive heart failure （CHF） with ventricular arrhythmia is limited.In the study,our aim was to evaluate the effects of Chinese traditional medicine Shensong Yangxin capsules （SSYX） on heart rhythm and function in CHF patients with frequent ventricular premat...
Saved in:
Cover
Loading…
| Abstract | Background：Pharmacological therapy for congestive heart failure （CHF） with ventricular arrhythmia is limited.In the study,our aim was to evaluate the effects of Chinese traditional medicine Shensong Yangxin capsules （SSYX） on heart rhythm and function in CHF patients with frequent ventricular premature complexes （VPCs）.Methods：This double-blind,placebo-controlled,multicenter study randomized 465 CHF patients with frequent VPCs to the SSYX （n =232） and placebo groups （n =233） for 12 weeks of treatment.The primary endpoint was the VPCs monitored by a 24-h ambulatory electrocardiogram.The secondary endpoints included the left ventricular ejection fraction （LVEF）,left ventricular end-diastolic diameter,N-terminal pro-brain natriuretic peptide （NT-proBNP）,New York Heart Association （NYHA） classification,6-min walking distance （6MWD）,Minnesota Living with Heart Failure Questionnaire （MLHFQ） scores,and composite cardiac events （CCEs）.Results：The clinical characteristics were similar at baseline.SSYX caused a significantly greater decline in the total number of VPCs than the placebo did （-2145 ± 2848 vs.-841 ± 3411,P 〈 0.05）.The secondary endpoints of the LVEE NYHA classification,NT-proBNP,6MWD,and MLHFQ scores showed a greater improvements in the SSYX group than in the placebo group （ALVEF at 12th week：4.75 ± 7.13 vs.3.30 ± 6.53;NYHA improvement rate at the 8th and 12th week：32.6% vs.21.8%,40.5% vs.25.7%;mean level of NT-proBNP in patients with NT-proBNP 〉125 pg/ml at 12th week：-122 [Q1,Q3：-524,0] vs.-75 [Q1,Q3：-245,0];A6MWD at 12th week：35.1 ± 38.6 vs.17.2 ± 45.6;AMLHFQ at the 4th,8th,and 12th week：-4.24 ± 6.15 vs.-2.31 ± 6.96,-8.l 9 ± 8.41 vs.-3.25 ± 9.40,10.60 ± 9.41 vs.-4.83 ± 11.23,all P 〈 0.05）.CCEs were not different between the groups during the study period.Conclusions：In this 12-week pilot study,SSYX was demonstrated to have the benefits of VPCs suppression and cardiac function improvement with good compliance on a background of standard treatment for CHF. |
|---|---|
| AbstractList | Background:Pharmacological therapy for congestive heart failure (CHF) with ventricular arrhythmia is limited.In the study,our aim was to evaluate the effects of Chinese traditional medicine Shensong Yangxin capsules (SSYX) on heart rhythm and function in CHF patients with frequent ventricular premature complexes (VPCs).Methods:This double-blind,placebo-controlled,multicenter study randomized 465 CHF patients with frequent VPCs to the SSYX (n =232) and placebo groups (n =233) for 12 weeks of treatment.The primary endpoint was the VPCs monitored by a 24-h ambulatory electrocardiogram.The secondary endpoints included the left ventricular ejection fraction (LVEF),left ventricular end-diastolic diameter,N-terminal pro-brain natriuretic peptide (NT-proBNP),New York Heart Association (NYHA) classification,6-min walking distance (6MWD),Minnesota Living with Heart Failure Questionnaire (MLHFQ) scores,and composite cardiac events (CCEs).Results:The clinical characteristics were similar at baseline.SSYX caused a significantly greater decline in the total number of VPCs than the placebo did (-2145 ± 2848 vs.-841 ± 3411,P ＜ 0.05).The secondary endpoints of the LVEE NYHA classification,NT-proBNP,6MWD,and MLHFQ scores showed a greater improvements in the SSYX group than in the placebo group (ALVEF at 12th week:4.75 ± 7.13 vs.3.30 ± 6.53;NYHA improvement rate at the 8th and 12th week:32.6％ vs.21.8％,40.5％ vs.25.7％;mean level of NT-proBNP in patients with NT-proBNP ＞125 pg/ml at 12th week:-122 [Q1,Q3:-524,0] vs.-75 [Q1,Q3:-245,0];A6MWD at 12th week:35.1 ± 38.6 vs.17.2 ± 45.6;AMLHFQ at the 4th,8th,and 12th week:-4.24 ± 6.15 vs.-2.31 ± 6.96,-8.l 9 ± 8.41 vs.-3.25 ± 9.40,10.60 ± 9.41 vs.-4.83 ± 11.23,all P ＜ 0.05).CCEs were not different between the groups during the study period.Conclusions:In this 12-week pilot study,SSYX was demonstrated to have the benefits of VPCs suppression and cardiac function improvement with good compliance on a background of standard treatment for CHF. BACKGROUNDPharmacological therapy for congestive heart failure (CHF) with ventricular arrhythmia is limited. In the study, our aim was to evaluate the effects of Chinese traditional medicine Shensong Yangxin capsules (SSYX) on heart rhythm and function in CHF patients with frequent ventricular premature complexes (VPCs).METHODSThis double-blind, placebo-controlled, multicenter study randomized 465 CHF patients with frequent VPCs to the SSYX (n = 232) and placebo groups (n = 233) for 12 weeks of treatment. The primary endpoint was the VPCs monitored by a 24-h ambulatory electrocardiogram. The secondary endpoints included the left ventricular ejection fraction (LVEF), left ventricular end-diastolic diameter, N-terminal pro-brain natriuretic peptide (NT-proBNP), New York Heart Association (NYHA) classification, 6-min walking distance (6MWD), Minnesota Living with Heart Failure Questionnaire (MLHFQ) scores, and composite cardiac events (CCEs).RESULTSThe clinical characteristics were similar at baseline. SSYX caused a significantly greater decline in the total number of VPCs than the placebo did (-2145 ± 2848 vs. -841 ± 3411, P < 0.05). The secondary endpoints of the LVEF, NYHA classification, NT-proBNP, 6MWD, and MLHFQ scores showed a greater improvements in the SSYX group than in the placebo group (ΔLVEF at 12th week: 4.75 ± 7.13 vs. 3.30 ± 6.53; NYHA improvement rate at the 8th and 12th week: 32.6% vs. 21.8%, 40.5% vs. 25.7%; mean level of NT-proBNP in patients with NT-proBNP ≥125 pg/ml at 12th week: -122 [Q1, Q3: -524, 0] vs. -75 [Q1, Q3: -245, 0]; Δ6MWD at 12th week: 35.1 ± 38.6 vs. 17.2 ± 45.6; ΔMLHFQ at the 4th, 8th, and 12th week: -4.24 ± 6.15 vs. -2.31 ± 6.96, -8.19 ± 8.41 vs. -3.25 ± 9.40, -10.60 ± 9.41 vs. -4.83 ± 11.23, all P < 0.05). CCEs were not different between the groups during the study period.CONCLUSIONSIn this 12-week pilot study, SSYX was demonstrated to have the benefits of VPCs suppression and cardiac function improvement with good compliance on a background of standard treatment for CHF.TRIAL REGISTRATIONwww.chictr.org.cn, ChiCTR-TRC-12002061 (http://www.chictr.org.cn/showproj.aspx?proj=7487) and Clinicaltrials.gov, NCT01612260 (https://clinicaltrials.gov/ct2/show/NCT01612260). Background: Pharmacological therapy for congestive heart failure (CHF) with ventricular arrhythmia is limited. In the study, our aim was to evaluate the effects of Chinese traditional medicine Shensong Yangxin capsules (SSYX) on heart rhythm and function in CHF patients with frequent ventricular premature complexes (VPCs). Methods: This double-blind, placebo-controlled, multicenter study randomized 465 CHF patients with frequent VPCs to the SSYX (n = 232) and placebo groups (n = 233) for 12 weeks of treatment. The primary endpoint was the VPCs monitored by a 24-h ambulatory electrocardiogram. The secondary endpoints included the left ventricular ejection fraction (LVEF), left ventricular end-diastolic diameter, N-terminal pro-brain natriuretic peptide (NT-proBNP), New York Heart Association (NYHA) classification, 6-min walking distance (6MWD), Minnesota Living with Heart Failure Questionnaire (MLHFQ) scores, and composite cardiac events (CCEs). Results: The clinical characteristics were similar at baseline. SSYX caused a significantly greater decline in the total number of VPCs than the placebo did (-2145 +- 2848 vs. -841 +- 3411, P < 0.05). The secondary endpoints of the LVEF, NYHA classification, NT-proBNP, 6MWD, and MLHFQ scores showed a greater improvements in the SSYX group than in the placebo group (ΔLVEF at 12th week: 4.75 +- 7.13 vs. 3.30 +- 6.53; NYHA improvement rate at the 8th and 12th week: 32.6% vs. 21.8%, 40.5% vs. 25.7%; mean level of NT-proBNP in patients with NT-proBNP >125 pg/ml at 12th week: -122 [Q1, Q3: -524, 0] vs. -75 [Q1, Q3: -245, 0]; Δ6MWD at 12th week: 35.1 +- 38.6 vs. 17.2 +- 45.6; ΔMLHFQ at the 4th , 8th , and 12th week: -4.24 +- 6.15 vs. -2.31 +- 6.96, -8.19 +- 8.41 vs. -3.25 +- 9.40, -10.60 +- 9.41 vs. -4.83 +- 11.23, all P < 0.05). CCEs were not different between the groups during the study period. Conclusions: In this 12-week pilot study, SSYX was demonstrated to have the benefits of VPCs suppression and cardiac function improvement with good compliance on a background of standard treatment for CHF. Trial Registration: www.chictr.org.cn, ChiCTR-TRC-12002061 (http://www.chictr.org.cn/showproj.aspx?proj=7487) and Clinicaltrials.gov, NCT01612260 (https://clinicaltrials.gov/ct2/show/NCT01612260). Background: Pharmacological therapy for congestive heart failure (CHF) with ventricular arrhythmia is limited. In the study, our aim was to evaluate the effects of Chinese traditional medicine Shensong Yangxin capsules (SSYX) on heart rhythm and function in CHF patients with frequent ventricular premature complexes (VPCs). Methods: This double-blind, placebo-controlled, multicenter study randomized 465 CHF patients with frequent VPCs to the SSYX (n = 232) and placebo groups (n = 233) for 12 weeks of treatment. The primary endpoint was the VPCs monitored by a 24-h ambulatory electrocardiogram. The secondary endpoints included the left ventricular ejection fraction (LVEF), left ventricular end-diastolic diameter, N-terminal pro-brain natriuretic peptide (NT-proBNP), New York Heart Association (NYHA) classification, 6-min walking distance (6MWD), Minnesota Living with Heart Failure Questionnaire (MLHFQ) scores, and composite cardiac events (CCEs). Results: The clinical characteristics were similar at baseline. SSYX caused a significantly greater decline in the total number of VPCs than the placebo did (−2145 ± 2848 vs. −841 ± 3411, P < 0.05). The secondary endpoints of the LVEF, NYHA classification, NT-proBNP, 6MWD, and MLHFQ scores showed a greater improvements in the SSYX group than in the placebo group (ΔLVEF at 12th week: 4.75 ± 7.13 vs. 3.30 ± 6.53; NYHA improvement rate at the 8th and 12th week: 32.6% vs. 21.8%, 40.5% vs. 25.7%; mean level of NT-proBNP in patients with NT-proBNP ≥125 pg/ml at 12th week: −122 [Q1, Q3: −524, 0] vs. −75 [Q1, Q3: −245, 0]; Δ6MWD at 12th week: 35.1 ± 38.6 vs. 17.2 ± 45.6; ΔMLHFQ at the 4th, 8th, and 12th week: −4.24 ± 6.15 vs. −2.31 ± 6.96, −8.19 ± 8.41 vs. −3.25 ± 9.40, −10.60 ± 9.41 vs. −4.83 ± 11.23, all P < 0.05). CCEs were not different between the groups during the study period. Conclusions: In this 12-week pilot study, SSYX was demonstrated to have the benefits of VPCs suppression and cardiac function improvement with good compliance on a background of standard treatment for CHF. Trial Registration: www.chictr.org.cn, ChiCTR-TRC-12002061 (http://www.chictr.org.cn/showproj.aspx?proj=7487) and Clinicaltrials.gov, NCT01612260 (\https://clinicaltrials.gov/ct2/show/NCT01612260). Background：Pharmacological therapy for congestive heart failure （CHF） with ventricular arrhythmia is limited.In the study,our aim was to evaluate the effects of Chinese traditional medicine Shensong Yangxin capsules （SSYX） on heart rhythm and function in CHF patients with frequent ventricular premature complexes （VPCs）.Methods：This double-blind,placebo-controlled,multicenter study randomized 465 CHF patients with frequent VPCs to the SSYX （n =232） and placebo groups （n =233） for 12 weeks of treatment.The primary endpoint was the VPCs monitored by a 24-h ambulatory electrocardiogram.The secondary endpoints included the left ventricular ejection fraction （LVEF）,left ventricular end-diastolic diameter,N-terminal pro-brain natriuretic peptide （NT-proBNP）,New York Heart Association （NYHA） classification,6-min walking distance （6MWD）,Minnesota Living with Heart Failure Questionnaire （MLHFQ） scores,and composite cardiac events （CCEs）.Results：The clinical characteristics were similar at baseline.SSYX caused a significantly greater decline in the total number of VPCs than the placebo did （-2145 ± 2848 vs.-841 ± 3411,P 〈 0.05）.The secondary endpoints of the LVEE NYHA classification,NT-proBNP,6MWD,and MLHFQ scores showed a greater improvements in the SSYX group than in the placebo group （ALVEF at 12th week：4.75 ± 7.13 vs.3.30 ± 6.53;NYHA improvement rate at the 8th and 12th week：32.6% vs.21.8%,40.5% vs.25.7%;mean level of NT-proBNP in patients with NT-proBNP 〉125 pg/ml at 12th week：-122 [Q1,Q3：-524,0] vs.-75 [Q1,Q3：-245,0];A6MWD at 12th week：35.1 ± 38.6 vs.17.2 ± 45.6;AMLHFQ at the 4th,8th,and 12th week：-4.24 ± 6.15 vs.-2.31 ± 6.96,-8.l 9 ± 8.41 vs.-3.25 ± 9.40,10.60 ± 9.41 vs.-4.83 ± 11.23,all P 〈 0.05）.CCEs were not different between the groups during the study period.Conclusions：In this 12-week pilot study,SSYX was demonstrated to have the benefits of VPCs suppression and cardiac function improvement with good compliance on a background of standard treatment for CHF. Pharmacological therapy for congestive heart failure (CHF) with ventricular arrhythmia is limited. In the study, our aim was to evaluate the effects of Chinese traditional medicine Shensong Yangxin capsules (SSYX) on heart rhythm and function in CHF patients with frequent ventricular premature complexes (VPCs). This double-blind, placebo-controlled, multicenter study randomized 465 CHF patients with frequent VPCs to the SSYX (n = 232) and placebo groups (n = 233) for 12 weeks of treatment. The primary endpoint was the VPCs monitored by a 24-h ambulatory electrocardiogram. The secondary endpoints included the left ventricular ejection fraction (LVEF), left ventricular end-diastolic diameter, N-terminal pro-brain natriuretic peptide (NT-proBNP), New York Heart Association (NYHA) classification, 6-min walking distance (6MWD), Minnesota Living with Heart Failure Questionnaire (MLHFQ) scores, and composite cardiac events (CCEs). The clinical characteristics were similar at baseline. SSYX caused a significantly greater decline in the total number of VPCs than the placebo did (-2145 ± 2848 vs. -841 ± 3411, P < 0.05). The secondary endpoints of the LVEF, NYHA classification, NT-proBNP, 6MWD, and MLHFQ scores showed a greater improvements in the SSYX group than in the placebo group (ΔLVEF at 12th week: 4.75 ± 7.13 vs. 3.30 ± 6.53; NYHA improvement rate at the 8th and 12th week: 32.6% vs. 21.8%, 40.5% vs. 25.7%; mean level of NT-proBNP in patients with NT-proBNP ≥125 pg/ml at 12th week: -122 [Q1, Q3: -524, 0] vs. -75 [Q1, Q3: -245, 0]; Δ6MWD at 12th week: 35.1 ± 38.6 vs. 17.2 ± 45.6; ΔMLHFQ at the 4th, 8th, and 12th week: -4.24 ± 6.15 vs. -2.31 ± 6.96, -8.19 ± 8.41 vs. -3.25 ± 9.40, -10.60 ± 9.41 vs. -4.83 ± 11.23, all P < 0.05). CCEs were not different between the groups during the study period. In this 12-week pilot study, SSYX was demonstrated to have the benefits of VPCs suppression and cardiac function improvement with good compliance on a background of standard treatment for CHF. www.chictr.org.cn, ChiCTR-TRC-12002061 (http://www.chictr.org.cn/showproj.aspx?proj=7487) and Clinicaltrials.gov, NCT01612260 (https://clinicaltrials.gov/ct2/show/NCT01612260). |
| Audience | Academic |
| Author | Xi Wang Dan HU Song Dang He Huang Cong-Xin Huang Ming-Jie Yuan Yan-Hong Tang Qing-Shan Zheng Fang Yin Shu Zhang Bo-Li Zhang Run-Lin Gao |
| AuthorAffiliation | Department of Cardiology, Cardiovascular Research Institute, Renmin Hospital of Wuhan University, Wuhan University, Wuhan, Hubei 430060, China Department of Cardiology, Cardiovascular Research Institute, Renmin Hospital of Wuhan University, Wuhan University, Wuhan, Hubei 430060, China;Department of Experimental Cardiology, Masonic Medical Research Laboratory, Utica, NY 13501, USA Center for Drug Clinical Research, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China National Center for Cardiovascular Disease, Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100037, China State Key Laboratory of Modern Chinese Medicine, College of Traditional Chinese Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin 300193, China |
| AuthorAffiliation_xml | – name: Department of Cardiology, Cardiovascular Research Institute, Renmin Hospital of Wuhan University, Wuhan University, Wuhan, Hubei 430060, China%Department of Cardiology, Cardiovascular Research Institute, Renmin Hospital of Wuhan University, Wuhan University, Wuhan, Hubei 430060, China;Department of Experimental Cardiology, Masonic Medical Research Laboratory, Utica, NY 13501, USA%Center for Drug Clinical Research, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China%National Center for Cardiovascular Disease, Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100037, China%State Key Laboratory of Modern Chinese Medicine, College of Traditional Chinese Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin 300193, China – name: 2 Department of Experimental Cardiology, Masonic Medical Research Laboratory, Utica, NY 13501, USA – name: 1 Department of Cardiology, Cardiovascular Research Institute, Renmin Hospital of Wuhan University, Wuhan University, Wuhan, Hubei 430060, China – name: 3 Center for Drug Clinical Research, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China – name: 4 National Center for Cardiovascular Disease, Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100037, China – name: 5 State Key Laboratory of Modern Chinese Medicine, College of Traditional Chinese Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin 300193, China |
| Author_xml | – sequence: 1 givenname: Xi surname: Wang fullname: Wang, Xi organization: Department of Cardiology, Cardiovascular Research Institute, Renmin Hospital of Wuhan University, Wuhan University, Wuhan, Hubei 430060, China – sequence: 2 givenname: Dan surname: Hu fullname: Hu, Dan organization: Department of Cardiology, Cardiovascular Research Institute, Renmin Hospital of Wuhan University, Wuhan University, Wuhan, Hubei 430060, China; Department of Experimental Cardiology, Masonic Medical Research Laboratory, Utica, NY 13501, USA – sequence: 3 givenname: Song surname: Dang fullname: Dang, Song organization: Department of Cardiology, Cardiovascular Research Institute, Renmin Hospital of Wuhan University, Wuhan University, Wuhan, Hubei 430060, China – sequence: 4 givenname: He surname: Huang fullname: Huang, He organization: Department of Cardiology, Cardiovascular Research Institute, Renmin Hospital of Wuhan University, Wuhan University, Wuhan, Hubei 430060, China – sequence: 5 givenname: Cong-Xin surname: Huang fullname: Huang, Cong-Xin organization: Department of Cardiology, Cardiovascular Research Institute, Renmin Hospital of Wuhan University, Wuhan University, Wuhan, Hubei 430060, China – sequence: 6 givenname: Ming-Jie surname: Yuan fullname: Yuan, Ming-Jie organization: Department of Cardiology, Cardiovascular Research Institute, Renmin Hospital of Wuhan University, Wuhan University, Wuhan, Hubei 430060, China – sequence: 7 givenname: Yan-Hong surname: Tang fullname: Tang, Yan-Hong organization: Department of Cardiology, Cardiovascular Research Institute, Renmin Hospital of Wuhan University, Wuhan University, Wuhan, Hubei 430060, China – sequence: 8 givenname: Qing-Shan surname: Zheng fullname: Zheng, Qing-Shan organization: Center for Drug Clinical Research, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China – sequence: 9 givenname: Fang surname: Yin fullname: Yin, Fang organization: Center for Drug Clinical Research, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China – sequence: 10 givenname: Shu surname: Zhang fullname: Zhang, Shu organization: National Center for Cardiovascular Disease, Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100037, China – sequence: 11 givenname: Bo-Li surname: Zhang fullname: Zhang, Bo-Li organization: State Key Laboratory of Modern Chinese Medicine, College of Traditional Chinese Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin 300193, China – sequence: 12 givenname: Run-Lin surname: Gao fullname: Gao, Run-Lin organization: National Center for Cardiovascular Disease, Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100037, China |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/28685712$$D View this record in MEDLINE/PubMed |
| BookMark | eNptk9tu1DAQhiMEoge45wpZIFVcsMXOwUlukKqlSyu1oioFiSvL60w2Xjn21k56ehSehSfihldgwm6XLkKRnNj-5nf8z8xO9Ng6C1H0gtH9lNHkHU04H_GyLPdjWpaUP4q24yyNRxlP2eNoe729Fe2EMKc0zrKcP4224oIXWc7i7ejnYV2D6gJxNbnwstKddlYaMm60hQDkFCqt8JN8bsAGZ2fkm7SzG23JWC5CbwAjLTkC6Tty3tx2TUukrcikt2pQIgOIURA6fQUrbiK16T2QM9lpsHj2te4aMvFw2eOUfMXBa9Ub6cmZh1Z2Azx27cLADYRfP74fkHM8xLX6Dqq35IPrpwZGU6Mtzk5702mFEuDJGJe0wttceC3Ns-hJLU2A56v3bvRlcngxPhqdfPp4PD44GSl0pxsVcVWrPOVJDaygBY68zOocgCWFLKaySlgqU5ZJkAwyKDgaCQBxqfK8grJIdqPjpW7l5FwsvG6lvxVOavFnwfmZQBe0MiBUXsgaJGesrtOcsZJKDpXKaZXwaSmnqPV-qbXopy3uDNZIsyG6uWN1I2buSmRZTLO0RIG9pcC1tDVmTsxd7zHBQdw1qp3HlOUspZQh-GZ1kneYh9CJVgcFxkgLrg-ClSzHcqIxRfT1P-halJVYfzlakv2lZhJvqm3t8AfVICoO0rLI44wnA7X_HwqfClqtsNprjesbAXsPAhqQpmuCM_1QbWETpEtQeReCh3rtGqNi6B4xtIcY2kMsuwdDXj50ex1w3y4IvFppNljUlxr9vGd4PlDoUfIbj8UmoA |
| Cites_doi | 10.1007/BF02836514 10.1016/j.atherosclerosis.2011.06.041 10.1016/j.hrthm.2012.10.011 10.1111/j.1476-5381.2009.00377.x 10.1016/j.jep.2014.09.035 10.3760/cma.j.issn.0366-6999.20130135 10.1016/j.amjcard.2011.08.009 10.1097/00029330-200706020-00008 10.1054/jcaf.2002.32946 10.1023/A:1027343606509 10.1016/j.cardfail.2012.11.004 10.1007/s11684-011-0140-z 10.2165/11594300-000000000-00000 10.3892/mmr.2015.4598 10.1016/j.amjcard.2012.05.016 10.1136/hrt.2005.067843 10.1016/j.amjcard.2014.07.072 10.3760/cma.j.issn.0366-6999.2011.1.015 10.1056/NEJM197710062971404 10.1056/NEJM199507133330201 10.1080/10286020.2015.1047354 10.1093/chromsci/bmu047 10.1002/bmc.3064 10.1111/j.1540-8167.2000.tb01802.x 10.1016/j.jacc.2013.06.012 10.1056/NEJM199605233342101 10.1111/j.1542-474X.1997.tb00199.x 10.1111/j.1542-474X.2007.00204.x 10.1016/S0735-1097(99)00234-X 10.1016/j.ejphar.2008.06.005 10.1016/0002-9149(90)90125-K |
| ContentType | Journal Article |
| Copyright | COPYRIGHT 2017 Medknow Publications and Media Pvt. Ltd. Copyright Medknow Publications & Media Pvt. Ltd. Jul 20, 2017 Copyright © Wanfang Data Co. Ltd. All Rights Reserved. Copyright: © 2017 Chinese Medical Journal 2017 |
| Copyright_xml | – notice: COPYRIGHT 2017 Medknow Publications and Media Pvt. Ltd. – notice: Copyright Medknow Publications & Media Pvt. Ltd. Jul 20, 2017 – notice: Copyright © Wanfang Data Co. Ltd. All Rights Reserved. – notice: Copyright: © 2017 Chinese Medical Journal 2017 |
| CorporateAuthor | Efficacy and Safety of Shensong Yangxin Capsules for Frequent VPCs in Congestive Heart Failure Study Group |
| CorporateAuthor_xml | – name: Efficacy and Safety of Shensong Yangxin Capsules for Frequent VPCs in Congestive Heart Failure Study Group |
| DBID | 2RA 92L CQIGP W91 ~WA CGR CUY CVF ECM EIF NPM AAYXX CITATION 3V. 7X7 7XB 88E 8FI 8FJ 8FK ABUWG AFKRA AZQEC BENPR CCPQU DWQXO FYUFA GHDGH K9. M0S M1P PIMPY PQEST PQQKQ PQUKI PRINS 7X8 2B. 4A8 92I 93N PSX TCJ 5PM DOA |
| DOI | 10.4103/0366-6999.209906 |
| DatabaseName | 中文科技期刊数据库 中文科技期刊数据库-CALIS站点 中文科技期刊数据库-7.0平台 中文科技期刊数据库-医药卫生 中文科技期刊数据库- 镜像站点 Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef ProQuest Central (Corporate) Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central ProQuest Central Essentials ProQuest Databases ProQuest One Community College ProQuest Central Korea Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Health & Medical Complete (Alumni) Health & Medical Collection (Alumni Edition) Medical Database Publicly Available Content Database ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic Wanfang Data Journals - Hong Kong WANFANG Data Centre Wanfang Data Journals 万方数据期刊 - 香港版 China Online Journals (COJ) China Online Journals (COJ) PubMed Central (Full Participant titles) DAOJ: Directory of Open Access Journals |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef Publicly Available Content Database ProQuest Central Essentials ProQuest One Academic Eastern Edition ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Central China ProQuest Hospital Collection (Alumni) ProQuest Central ProQuest Health & Medical Complete Health Research Premium Collection ProQuest Medical Library ProQuest One Academic UKI Edition Health and Medicine Complete (Alumni Edition) ProQuest Central Korea ProQuest One Academic ProQuest Medical Library (Alumni) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic Publicly Available Content Database MEDLINE |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 4 dbid: 7X7 name: Health & Medical Collection url: https://search.proquest.com/healthcomplete sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| DocumentTitleAlternate | Effects of Traditional Chinese Medicine Shensong Yangxin Capsules on Heart Rhythm and Function in Congestive Heart Failure Patients with Frequent Ventricular Premature Complexes：A Randomized, Double-blind, Multicenter Clinical Trial |
| EISSN | 2542-5641 |
| EndPage | 1647 |
| ExternalDocumentID | oai_doaj_org_article_c78afea611ff471190a6edc70d36b9ab zhcmj201714001 A498725635 10_4103_0366_6999_209906 28685712 672868173 |
| Genre | Multicenter Study Journal Article |
| GeographicLocations | China |
| GeographicLocations_xml | – name: China |
| GrantInformation_xml | – fundername: The study was supported by a grant from the 973 Program of China funderid: (2012CN518606) |
| GroupedDBID | --- -05 -0E -SE -S~ .55 .GJ 29B 2B. 2C~ 2RA 2WC 3V. 40I 53G 5GY 5RE 5VR 5VS 6J9 7X7 88E 8FI 8FJ 92F 92I 92L 92M 93N 93R 9D9 9DE AAHPQ AASCR ABASU ABCQX ABDIG ABUWG ABVCZ ABXLX ACGFO ACGFS ACILI ADGGA ADHPY ADPDF ADRAZ AENEX AFDTB AFKRA AFUIB AHMBA AHVBC AINUH AJIOK AJNWD ALMA_UNASSIGNED_HOLDINGS ALMTX AMJPA AMKUR AMNEI ANFDX AOHHW BENPR BPHCQ BVXVI C1A CAJEE CAJUS CCEZO CCPQU CHBEP CIEJG CQIGP CW9 DIK DIWNM EBS EEVPB EJD F5P FA0 FCALG FRP FYUFA GNXGY GQDEL GROUPED_DOAJ GX1 HLJTE HMCUK HYE IAO IHR IHW IKREB INH INR IPNFZ ITC JUIAU KQ8 L7B M1P M48 OK1 OPUJH OVD OVDNE OVEED OXXIT P2P P6G PIMPY PQQKQ PROAC PSQYO PV9 Q-- Q-4 R-E RIG RLZ RNS RPM RT5 RZL S.. T8U TCJ TEORI TGQ TR2 TSPGW U1F U1G U5E U5O UKHRP W2D W91 WFFXF X7J X7M XSB ZA5 ZGI ZXP ~WA 0R~ AAAAV AAIQE ACXJB AHQNM AJZMW ALIPV CGR CUY CVF ECM EIF H13 NPM AAYXX CITATION 7XB 8FK AZQEC BQLVK DWQXO K9. PQEST PQUKI PRINS 7X8 4A8 PSX 5PM |
| ID | FETCH-LOGICAL-c557t-82dfc7463fe1808fe1695f7ee138a8bad314a415aea1e5e86571eee29c77de983 |
| IEDL.DBID | RPM |
| ISSN | 0366-6999 |
| IngestDate | Fri Oct 04 13:12:06 EDT 2024 Tue Sep 17 20:59:16 EDT 2024 Tue Feb 13 23:39:43 EST 2024 Fri Aug 16 23:54:37 EDT 2024 Mon Oct 07 11:25:28 EDT 2024 Thu Feb 22 23:28:51 EST 2024 Wed Jan 10 04:07:17 EST 2024 Tue Aug 20 22:08:14 EDT 2024 Thu Aug 22 14:24:12 EDT 2024 Sat Sep 28 08:46:24 EDT 2024 Wed Feb 14 09:58:22 EST 2024 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 14 |
| Keywords | Ventricular Premature Complexes Congestive Heart Failure Randomized Controlled Trial Shensong Yangxin Capsules |
| Language | English |
| License | This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c557t-82dfc7463fe1808fe1695f7ee138a8bad314a415aea1e5e86571eee29c77de983 |
| Notes | Background：Pharmacological therapy for congestive heart failure （CHF） with ventricular arrhythmia is limited.In the study,our aim was to evaluate the effects of Chinese traditional medicine Shensong Yangxin capsules （SSYX） on heart rhythm and function in CHF patients with frequent ventricular premature complexes （VPCs）.Methods：This double-blind,placebo-controlled,multicenter study randomized 465 CHF patients with frequent VPCs to the SSYX （n =232） and placebo groups （n =233） for 12 weeks of treatment.The primary endpoint was the VPCs monitored by a 24-h ambulatory electrocardiogram.The secondary endpoints included the left ventricular ejection fraction （LVEF）,left ventricular end-diastolic diameter,N-terminal pro-brain natriuretic peptide （NT-proBNP）,New York Heart Association （NYHA） classification,6-min walking distance （6MWD）,Minnesota Living with Heart Failure Questionnaire （MLHFQ） scores,and composite cardiac events （CCEs）.Results：The clinical characteristics were similar at baseline.SSYX caused a significantly greater decline in the total number of VPCs than the placebo did （-2145 ± 2848 vs.-841 ± 3411,P 〈 0.05）.The secondary endpoints of the LVEE NYHA classification,NT-proBNP,6MWD,and MLHFQ scores showed a greater improvements in the SSYX group than in the placebo group （ALVEF at 12th week：4.75 ± 7.13 vs.3.30 ± 6.53;NYHA improvement rate at the 8th and 12th week：32.6% vs.21.8%,40.5% vs.25.7%;mean level of NT-proBNP in patients with NT-proBNP 〉125 pg/ml at 12th week：-122 [Q1,Q3：-524,0] vs.-75 [Q1,Q3：-245,0];A6MWD at 12th week：35.1 ± 38.6 vs.17.2 ± 45.6;AMLHFQ at the 4th,8th,and 12th week：-4.24 ± 6.15 vs.-2.31 ± 6.96,-8.l 9 ± 8.41 vs.-3.25 ± 9.40,10.60 ± 9.41 vs.-4.83 ± 11.23,all P 〈 0.05）.CCEs were not different between the groups during the study period.Conclusions：In this 12-week pilot study,SSYX was demonstrated to have the benefits of VPCs suppression and cardiac function improvement with good compliance on a background of standard treatment for CHF. Congestive Heart Failure; Randomized ControlledTrial; Shensong Yangxin Capsules; Ventricular PrematureComplexes 11-2154/R ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| OpenAccessLink | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5520549/ |
| PMID | 28685712 |
| PQID | 1925476575 |
| PQPubID | 2042885 |
| PageCount | 9 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_c78afea611ff471190a6edc70d36b9ab pubmedcentral_primary_oai_pubmedcentral_nih_gov_5520549 wanfang_journals_zhcmj201714001 proquest_miscellaneous_1917366020 proquest_journals_1925476575 gale_infotracmisc_A498725635 gale_infotracacademiconefile_A498725635 gale_healthsolutions_A498725635 crossref_primary_10_4103_0366_6999_209906 pubmed_primary_28685712 chongqing_primary_672868173 |
| PublicationCentury | 2000 |
| PublicationDate | 2017-07-20 |
| PublicationDateYYYYMMDD | 2017-07-20 |
| PublicationDate_xml | – month: 07 year: 2017 text: 2017-07-20 day: 20 |
| PublicationDecade | 2010 |
| PublicationPlace | China |
| PublicationPlace_xml | – name: China – name: Baltimore – name: India |
| PublicationTitle | Chinese medical journal |
| PublicationTitleAlternate | Chinese Medical Journal |
| PublicationTitle_FL | Chinese Medical Journal |
| PublicationYear | 2017 |
| Publisher | Medknow Publications and Media Pvt. Ltd Lippincott Williams & Wilkins Ovid Technologies Department of Experimental Cardiology, Masonic Medical Research Laboratory, Utica, NY 13501, USA%Center for Drug Clinical Research, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China%National Center for Cardiovascular Disease, Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100037, China%State Key Laboratory of Modern Chinese Medicine, College of Traditional Chinese Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin 300193, China Department of Cardiology, Cardiovascular Research Institute, Renmin Hospital of Wuhan University, Wuhan University, Wuhan, Hubei 430060, China%Department of Cardiology, Cardiovascular Research Institute, Renmin Hospital of Wuhan University, Wuhan University, Wuhan, Hubei 430060, China Medknow Publications & Media Pvt Ltd Wolters Kluwer |
| Publisher_xml | – name: Medknow Publications and Media Pvt. Ltd – name: Lippincott Williams & Wilkins Ovid Technologies – name: Department of Cardiology, Cardiovascular Research Institute, Renmin Hospital of Wuhan University, Wuhan University, Wuhan, Hubei 430060, China%Department of Cardiology, Cardiovascular Research Institute, Renmin Hospital of Wuhan University, Wuhan University, Wuhan, Hubei 430060, China – name: Department of Experimental Cardiology, Masonic Medical Research Laboratory, Utica, NY 13501, USA%Center for Drug Clinical Research, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China%National Center for Cardiovascular Disease, Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100037, China%State Key Laboratory of Modern Chinese Medicine, College of Traditional Chinese Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin 300193, China – name: Medknow Publications & Media Pvt Ltd – name: Wolters Kluwer |
| References | 21945138 - Am J Cardiol. 2012 Jan 1;109(1):105-9 17041126 - Heart. 2006 Nov;92(11):1707-12 14618094 - Cardiovasc Drugs Ther. 2003 Jul;17 (4):325-33 18573250 - Eur J Pharmacol. 2008 Aug 20;590(1-3):317-21 12016631 - J Card Fail. 2002 Apr;8(2):79-85 24122893 - Biomed Chromatogr. 2014 Apr;28(4):525-33 26648261 - Mol Med Rep. 2016 Jan;13(1):980-8 17637224 - Chin Med J (Engl). 2007 Jun 20;120(12):1068-74 10440140 - J Am Coll Cardiol. 1999 Aug;34(2):325-33 23850913 - J Am Coll Cardiol. 2013 Sep 24;62(13):1195-202 17005073 - Chin J Integr Med. 2006 Sep;12(3):161-5 21985167 - Drugs. 2011 Oct 22;71(15):1989-2008 23099051 - Heart Rhythm. 2013 Feb;10 (2):172-5 21774934 - Atherosclerosis. 2012 Jan;220(1):3-10 28091409 - Chin Med J (Engl). 2017 20th Jan;130(2):171-178 21362312 - Chin Med J (Engl). 2011 Jan;124(1):76-83 24238534 - Chin Med J (Engl). 2013 Nov;126(22):4389-91 25267579 - J Ethnopharmacol. 2014 Nov 18;157:161-70 21695614 - Front Med. 2011 Jun;5(2):118-22 8614419 - N Engl J Med. 1996 May 23;334(21):1349-55 19775284 - Br J Pharmacol. 2009 Nov;158(5):1227-35 24872525 - J Chromatogr Sci. 2015 Feb;53(2):240-52 26166310 - J Asian Nat Prod Res. 2015 May;17(5):559-66 23273593 - J Card Fail. 2013 Jan;19(1):40-9 2159694 - Am J Cardiol. 1990 May 22;65(19):42I-48I 70750 - N Engl J Med. 1977 Oct 6;297(14):750-7 18234010 - Ann Noninvasive Electrocardiol. 2008 Jan;13(1):81-5 7539890 - N Engl J Med. 1995 Jul 13;333(2):77-82 22681866 - Am J Cardiol. 2012 Sep 15;110(6):852-6 25205629 - Am J Cardiol. 2014 Nov 1;114(9):1373-8 10749356 - J Cardiovasc Electrophysiol. 2000 Mar;11(3):328-9 19159580 - Zhonghua Yi Xue Za Zhi. 2008 Dec 30;88(48):3440-3 Ding (R6-1-20210129) 2015; 17 Yang (R29-1-20210129) 2013; 126 Agarwal (R12-1-20210129) 2012; 109 Chugh (R13-1-20210129) 2000; 11 Liu (R24-1-20210129) 2015; 53 Karmazyn (R34-1-20210129) 2011; 71 Liu (R25-1-20210129) 2014; 28 Shiga (R17-1-20210129) 2003; 17 Zou (R28-1-20210129) 2011; 124 Zhao (R33-1-20210129) 2017; 130 Li (R5-1-20210129) 2007; 120 Kjekshus (R14-1-20210129) 1990; 65 Penela (R30-1-20210129) 2013; 62 Exner (R19-1-20210129) 1999; 34 Ng (R22-1-20210129) 2006; 92 Gao (R35-1-20210129) 2012; 220 Singh (R16-1-20210129) 1995; 333 Sun (R37-1-20210129) 2008; 590 Ruberman (R15-1-20210129) 1977; 297 Chen (R21-1-20210129) 2013; 19 Aronson (R20-1-20210129) 2002; 8 Shan (R36-1-20210129) 2009; 158 Kanei (R11-1-20210129) 2008; 13 Jiang (R10-1-20210129) 2014; 28 Anastasiou-Nana (R1-1-20210129) 1997; 2 Shen (R8-1-20210129) 2014; 157 Shen (R9-1-20210129) 2016; 13 Lee (R2-1-20210129) 2014; 114 Chen (R3-1-20210129) 2006; 12 Packer (R18-1-20210129) 1996; 334 Yokokawa (R32-1-20210129) 2013; 10 Wang (R7-1-20210129) 2012; 16 Wu (R23-1-20210129) 2011; 5 Lü (R31-1-20210129) 2012; 110 Ren (R27-1-20210129) 2008; 88 |
| References_xml | – volume: 12 start-page: 161 year: 2006 ident: R3-1-20210129 article-title: Situation of integrative medicine in China: Results from a national survey in 2004 (in Chinese) publication-title: Chin J Integr Med doi: 10.1007/BF02836514 contributor: fullname: Chen – volume: 220 start-page: 3 year: 2012 ident: R35-1-20210129 article-title: Cardiovascular actions and therapeutic potential of tanshinone IIA publication-title: Atherosclerosis doi: 10.1016/j.atherosclerosis.2011.06.041 contributor: fullname: Gao – volume: 10 start-page: 172 year: 2013 ident: R32-1-20210129 article-title: Recovery from left ventricular dysfunction after ablation of frequent premature ventricular complexes publication-title: Heart Rhythm doi: 10.1016/j.hrthm.2012.10.011 contributor: fullname: Yokokawa – volume: 158 start-page: 1227 year: 2009 ident: R36-1-20210129 article-title: Tanshinone IIA protects against sudden cardiac death induced by lethal arrhythmias via repression of microRNA-1 publication-title: Br J Pharmacol doi: 10.1111/j.1476-5381.2009.00377.x contributor: fullname: Shan – volume: 157 start-page: 161 year: 2014 ident: R8-1-20210129 article-title: Shensong Yangxin capsule prevents diabetic myocardial fibrosis by inhibiting TGF-ß1/Smad signaling publication-title: J Ethnopharmacol doi: 10.1016/j.jep.2014.09.035 contributor: fullname: Shen – volume: 126 start-page: 4389 year: 2013 ident: R29-1-20210129 article-title: Effects of Shensongyangxin capsule on heart rate turbulence and heart rate variability in chronic heart failure publication-title: Chin Med J doi: 10.3760/cma.j.issn.0366-6999.20130135 contributor: fullname: Yang – volume: 109 start-page: 105 year: 2012 ident: R12-1-20210129 article-title: Relation of ventricular premature complexes to heart failure (from the Atherosclerosis Risk In Communities [ARIC] Study) publication-title: Am J Cardiol doi: 10.1016/j.amjcard.2011.08.009 contributor: fullname: Agarwal – volume: 120 start-page: 1068 year: 2007 ident: R5-1-20210129 article-title: Effects of Chinese herbs on multiple ion channels in isolated ventricular myocytes publication-title: Chin Med J doi: 10.1097/00029330-200706020-00008 contributor: fullname: Li – volume: 8 start-page: 79 year: 2002 ident: R20-1-20210129 article-title: Concomitant beta-blocker therapy is associated with a lower occurrence of ventricular arrhythmias in patients with decompensated heart failure publication-title: J Card Fail doi: 10.1054/jcaf.2002.32946 contributor: fullname: Aronson – volume: 17 start-page: 325 year: 2003 ident: R17-1-20210129 article-title: Amiodarone decreases plasma brain natriuretic peptide level in patients with heart failure and ventricular tachyarrhythmia publication-title: Cardiovasc Drugs Ther doi: 10.1023/A:1027343606509 contributor: fullname: Shiga – volume: 88 start-page: 3440 year: 2008 ident: R27-1-20210129 article-title: Effects of Shen-song-yang-xin capsule on ventricular arrhythmias in ischemia/reperfusion: Experiment with rats (in Chinese) publication-title: Nati Med J China contributor: fullname: Ren – volume: 19 start-page: 40 year: 2013 ident: R21-1-20210129 article-title: Ventricular ectopy in patients with left ventricular dysfunction: Should it be treated? publication-title: J Card Fail doi: 10.1016/j.cardfail.2012.11.004 contributor: fullname: Chen – volume: 28 start-page: 59 year: 2014 ident: R10-1-20210129 article-title: Effects of Shensong Yangxin on neural remodeling after myocardial infarction in rabbits (in Chinese) publication-title: Chin J Card Pacing Electrophysiol contributor: fullname: Jiang – volume: 5 start-page: 118 year: 2011 ident: R23-1-20210129 article-title: Construction of the vessel-collateral theory and its guidance for prevention and treatment of vasculopathy publication-title: Front Med doi: 10.1007/s11684-011-0140-z contributor: fullname: Wu – volume: 71 start-page: 1989 year: 2011 ident: R34-1-20210129 article-title: Therapeutic potential of Ginseng in the management of cardiovascular disorders publication-title: Drugs doi: 10.2165/11594300-000000000-00000 contributor: fullname: Karmazyn – volume: 13 start-page: 980 year: 2016 ident: R9-1-20210129 article-title: Shensongyangxin protects against pressure overload-induced cardiac hypertrophy publication-title: Mol Med Rep doi: 10.3892/mmr.2015.4598 contributor: fullname: Shen – volume: 110 start-page: 852 year: 2012 ident: R31-1-20210129 article-title: Effects of catheter ablation of “asymptomatic” frequent ventricular premature complexes in patients with reduced (<48%) left ventricular ejection fraction publication-title: Am J Cardiol doi: 10.1016/j.amjcard.2012.05.016 contributor: fullname: Lü – volume: 92 start-page: 1707 year: 2006 ident: R22-1-20210129 article-title: Treating patients with ventricular ectopic beats publication-title: Heart doi: 10.1136/hrt.2005.067843 contributor: fullname: Ng – volume: 114 start-page: 1373 year: 2014 ident: R2-1-20210129 article-title: Frequency, origin, and outcome of ventricular premature complexes in patients with or without heart diseases publication-title: Am J Cardiol doi: 10.1016/j.amjcard.2014.07.072 contributor: fullname: Lee – volume: 124 start-page: 76 year: 2011 ident: R28-1-20210129 article-title: Evaluation of the traditional Chinese medicine Shensongyangxin capsule on treating premature ventricular contractions: A randomized, double-blind, controlled multicenter trial publication-title: Chin Med J doi: 10.3760/cma.j.issn.0366-6999.2011.1.015 contributor: fullname: Zou – volume: 130 start-page: 171 year: 2017 ident: R33-1-20210129 article-title: Effect of Shensong Yangxin on the progression of paroxysmal atrial fibrillation is correlated with regulation of autonomic nerve activity publication-title: Chin Med J contributor: fullname: Zhao – volume: 297 start-page: 750 year: 1977 ident: R15-1-20210129 article-title: Ventricular premature beats and mortality after myocardial infarction publication-title: N Engl J Med doi: 10.1056/NEJM197710062971404 contributor: fullname: Ruberman – volume: 333 start-page: 77 year: 1995 ident: R16-1-20210129 article-title: Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia. Survival Trial of Antiarrhythmic Therapy in Congestive Heart Failure publication-title: N Engl J Med doi: 10.1056/NEJM199507133330201 contributor: fullname: Singh – volume: 17 start-page: 559 year: 2015 ident: R6-1-20210129 article-title: Spiroalkaloids from Shensong Yangxin capsule publication-title: J Asian Nat Prod Res doi: 10.1080/10286020.2015.1047354 contributor: fullname: Ding – volume: 53 start-page: 240 year: 2015 ident: R24-1-20210129 article-title: Identification of multiple constituents in Chinese medicinal prescription Shensong Yangxin capsule by ultra-fast liquid chromatography combined with quadrupole time-of-flight mass spectrometry publication-title: J Chromatogr Sci doi: 10.1093/chromsci/bmu047 contributor: fullname: Liu – volume: 28 start-page: 525 year: 2014 ident: R25-1-20210129 article-title: Studies on excretion kinetics of ten constituents in rat urine after oral administration of Shensong Yangxin capsule by UPLC-MS/MS publication-title: Biomed Chromatogr doi: 10.1002/bmc.3064 contributor: fullname: Liu – volume: 11 start-page: 328 year: 2000 ident: R13-1-20210129 article-title: First evidence of premature ventricular complex-induced cardiomyopathy: A potentially reversible cause of heart failure publication-title: J Cardiovasc Electrophysiol doi: 10.1111/j.1540-8167.2000.tb01802.x contributor: fullname: Chugh – volume: 16 start-page: 415 year: 2012 ident: R7-1-20210129 article-title: Effects of Shensong Yangxin (SSYX) on cardiac function and electrophysiological characteristics in rabbits (in Chinese) publication-title: Chin J Card Arrhythm contributor: fullname: Wang – volume: 62 start-page: 1195 year: 2013 ident: R30-1-20210129 article-title: Neurohormonal, structural, and functional recovery pattern after premature ventricular complex ablation is independent of structural heart disease status in patients with depressed left ventricular ejection fraction: A prospective multicenter study publication-title: J Am Coll Cardiol doi: 10.1016/j.jacc.2013.06.012 contributor: fullname: Penela – volume: 334 start-page: 1349 year: 1996 ident: R18-1-20210129 article-title: The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group publication-title: N Engl J Med doi: 10.1056/NEJM199605233342101 contributor: fullname: Packer – volume: 2 start-page: 346 year: 1997 ident: R1-1-20210129 article-title: Quantification of prevalence of asymptomatic ventricular arrhythmias in patients with heart failure publication-title: Ann Noninvasive Electrocardiol doi: 10.1111/j.1542-474X.1997.tb00199.x contributor: fullname: Anastasiou-Nana – volume: 13 start-page: 81 year: 2008 ident: R11-1-20210129 article-title: Frequent premature ventricular complexes originating from the right ventricular outflow tract are associated with left ventricular dysfunction publication-title: Ann Noninvasive Electrocardiol doi: 10.1111/j.1542-474X.2007.00204.x contributor: fullname: Kanei – volume: 34 start-page: 325 year: 1999 ident: R19-1-20210129 article-title: Beta-blocker use and survival in patients with ventricular fibrillation or symptomatic ventricular tachycardia: The Antiarrhythmics Versus Implantable Defibrillators (AVID) trial publication-title: J Am Coll Cardiol doi: 10.1016/S0735-1097(99)00234-X contributor: fullname: Exner – volume: 590 start-page: 317 year: 2008 ident: R37-1-20210129 article-title: Tanshinone IIA: A new activator of human cardiac KCNQ1/KCNE1 (I(Ks)) potassium channels publication-title: Eur J Pharmacol doi: 10.1016/j.ejphar.2008.06.005 contributor: fullname: Sun – volume: 65 start-page: 42I year: 1990 ident: R14-1-20210129 article-title: Arrhythmias and mortality in congestive heart failure publication-title: Am J Cardiol doi: 10.1016/0002-9149(90)90125-K contributor: fullname: Kjekshus |
| SSID | ssj0025576 |
| Score | 2.2968163 |
| Snippet | Background：Pharmacological therapy for congestive heart failure （CHF） with ventricular arrhythmia is limited.In the study,our aim was to evaluate the effects... Pharmacological therapy for congestive heart failure (CHF) with ventricular arrhythmia is limited. In the study, our aim was to evaluate the effects of Chinese... Background: Pharmacological therapy for congestive heart failure (CHF) with ventricular arrhythmia is limited. In the study, our aim was to evaluate the... BACKGROUNDPharmacological therapy for congestive heart failure (CHF) with ventricular arrhythmia is limited. In the study, our aim was to evaluate the effects... Background:Pharmacological therapy for congestive heart failure (CHF) with ventricular arrhythmia is limited.In the study,our aim was to evaluate the effects... |
| SourceID | doaj pubmedcentral wanfang proquest gale crossref pubmed chongqing |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Publisher |
| StartPage | 1639 |
| SubjectTerms | Adolescent Adult Aged Analysis Atherosclerosis Blood diseases Cardiac arrhythmia Cardiology Cardiovascular disease Care and treatment Chinese medicine Clinical trials Congestive heart failure Congestive Heart Failure; Randomized Controlled Trial; Shensong Yangxin Capsules; Ventricular Premature Complexes Double-Blind Method Double-blind studies Drug dosages Drugs, Chinese Herbal - therapeutic use Electrocardiography FDA approval Female Heart failure Heart Failure - drug therapy Heart Failure - metabolism Heart function tests Heart rate Heart Rate - drug effects Hospitals Humans Laboratories Male Medicine, Chinese Traditional - methods Middle Aged Original Patients Potassium Research centers Traditional Chinese medicine Ventricular ectopic beats Ventricular Function, Left - drug effects Ventricular Premature Complexes - drug therapy Ventricular Premature Complexes - metabolism Young Adult 充血性心力衰竭 室性 心脏节律 患者 松 胶囊 试验 随机 |
| SummonAdditionalLinks | – databaseName: DAOJ: Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9NAEF6hSiAuiDemBRYJCSFhmrW9D3MLFVGEVFQVisrJWq_HsavEgcSF0n_Mv2DGdkwMBy5cIsU7a3vH385jH98y9iwGjLEz6mlh7vxIq9Q3mbU-mBSToMAJp2i_8-F7NT2J3p3K062jvmhNWEsP3Cpu32ljc7BKiDxHQ4r-yyrInB5loUpjmzbWV8hNMtWlWlLqbpZS-QpjoHaCMhKjcL-_9op2jY4aUoViWc2-oqsYOKeGw_9vS73lqv5cRnn1u61yW822PNTkJrvRhZZ83DbpFrsC1W127bCbPL_DfrZMxWu-zDm6qKxshwE5HaENa-AbSf6hANoSNuOf8SkXZcUPLObSc8CaFZ9i16j5cfGjLhbcVhmfoGekO3ESxFpE2_ENOrmJLWndOz9q6VvXnMZ9-WTVLOCu-SdqU9ksheVHK6KPJWGyUXO4gPVrPubH-IzloryE7CXHaD-dg59iaIz_mr3DpBVY8Y7edI4Nww51l51M3n48mPrdSQ--wy9V-ybIcqcjFeYgzMjgr4plrgFEaKxJbRaKyGKoYcEKkGCU1AIAgthpnUFswntsp1pW8IDxVDinwkhHEmvESqQuxhTVgJBpmGKs5rHd_nMnX1pGj0TpwCgjqPTFBgB9IaZJBJyEgJMQcJIWOB57Qwjp5Yiou7mA8E06-Cb_gq_HnhC-knbXa29uknEUG43haCg99ryRIIODMHO22zeBzSXqroHk3kASDYUbFm8wnHSGap1ggC-xh2LQ7rGnfTHVpMV3FSzPSQY1oxQmFh6730K-bzTpDT9G4DE96AwDrQxLqrJoaMylDDBfiFEDXbf5_VaXhVucBUTlhC5GPPwfit5l1-mGNCwfjPbYTr06h0cYT9bp48Z0_AK_03T8 priority: 102 providerName: Directory of Open Access Journals – databaseName: Health & Medical Collection dbid: 7X7 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3db9MwELfGEIgXxDdhA4yEhJDIWufDdnhBY6KqkIamwdB4imzn0ha1ydZmMPYf819wl6TZAhIvlRqfk9i5j9_Zd2fGXiaAGDsjSQtz50dKWl9nxvigLTpBgRNOUr7z_ic5Poo-HsfHG2y8zoWhsMq1TqwVdVY6WiMfIBKJ8VaILgbG0iqAqwbvTk59Oj-K9lnbwzSusesiQFiBnK2OL12vOFbtrqX0JWKiZsMyEsNw0F3boSzSYV1kYVoWk1M0HT1jVdf0_1dzXzFdf4dV3vhpitwUkysWa3SH3W6hJt9teOMu24DiHru5326m32e_m8rFK17mHE1WNmuWBTkdqQ0r4GtK_nkKlCI24d_wKeezgu8Z9K3ngD0LPkZRqfjh9Fc1XXBTZHyElpLuxIkQe1EZjx_Q0o3MjOLg-UFTznXFaR2Yj5Z1QHfFv9KYZnVoLD9YUjlZIiadNYdzWL3lu_wQn1EuZheQveGI_u0cfItQGf_VucQ0K7DkbbnTOQ4MBewBOxp9-LI39tuTH3yHX6rydZDlTkUyzEHoocZfmcS5AhChNtqaLBSRQehhwAiIQSNbCAAIEqdUBokOH7LNoizgMeNWOCfDSEUx9kiksC5Bl1WDiG1oEbt5bKv73OlJU-EjlSrQUgtqfb1mgK4R3SZinJQYJyXGSRvG8dh74pCOjgp31xfK5SRt9UDqlDY5GClEniMuQDhmJHKMGmahtImxHntO_JU2WbCd-kl3o0QrhKdh7LFXNQUpIBID0-ZR4HCplFePcrtHiYrD9ZvXPJy2imuVXoqZx150zdSTgvEKKM-IBmdGSnQ0PPaoYflu0DRv-DECj6meMPRmpd9SzKZ1WfM4DtB_SHAGWrG5fKuLqVt8D6i0E5oc8eT_L77FbhEpLcAHw222WS3P4Ckix8o-q5XCH7aPbxY priority: 102 providerName: ProQuest – databaseName: Scholars Portal Open Access Journals dbid: M48 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3db9MwELfQEB8viG_CBhgJCSGRUufDdnhBZaKqkIqmQdF4ihzn0ga1KUs76PYf819wl6TZAnvipVLqsxM7v7v7XWyfGXsRAXLslDTNz6wbKJm4OjXGBZ1gEORZYSXtdx5_kqNJ8PEoPDrfHt0M4OrS0I7Ok5qU897m-PQdKjzy114g-v4bNMLSlch0erQPlPJvX_UCPyC8j4N2TgG5s2pmLmvpetLy0hYoRbCWOlR0UOUNfJRieoyepOO7qhT__xryC57s71WW136ZIjPF9IIDG95mtxrmyQc1VO6wK1DcZdfHzdz6Pfa7TmS84suMowdL8_orIacTtmEFfCvJP8-AdoxN-Te8yyYv-L7BUHsOWLPgI9ScNT-cna5nC26KlA_RcVJLnASxFmX1-AmN3NDktCyeH9TZXVecPgvzYVmt717zr9SnvFopyw9Kyi5LwmTC5rCB1Vs-4Id4j-UiP4P0NcdgIJmDmyBzxqtqazGNCpS8yX46x46hvt1nk-GHL_sjtzkIwrX40tau9tLMqkD6GQjd1_grozBTAMLXRicm9UVgkIkYMAJC0BJfHAB4kVUqhUj7D9hOsSzgEeOJsFb6gQpCrBFJkdgII1gNIkz8BKmcw3bb1x3_qBN-xFIRGgSVvtoCoC3EKIowFBOGYsJQXGPIYe8JIa0c5fGu_liW07gxC7FV2mRgpBBZhjQB2ZmRiBjVT32ZRCZx2DPCV1xvim2tUTwIIq2Qrfqhw15WEqQhCDNrmm0V2F3K7NWR3OtIoh2x3eIthuOtGsbI_0NUYOT0DnveFlNNWptXwPKEZHBkpMS4w2EPa8i3nd5qkcNURxk6o9ItKfJZleU8DD0MJyIcgUZtzp_qbGYX3z3K9IQeSDz-77Z32U1qhT7Ve_09trMuT-AJcsx18rQyHX8ATLR7SA priority: 102 providerName: Scholars Portal |
| Title | Effects of Traditional Chinese Medicine Shensong Yangxin Capsules on Heart Rhythm and Function in Congestive Heart Failure Patients with Frequent Ventricular Premature Complexes：A Randomized, Double-blind, Multicenter Clinical Trial |
| URI | http://lib.cqvip.com/qk/85656X/201714/672868173.html https://www.ncbi.nlm.nih.gov/pubmed/28685712 https://www.proquest.com/docview/1925476575/abstract/ https://search.proquest.com/docview/1917366020 https://d.wanfangdata.com.cn/periodical/zhcmj201714001 https://pubmed.ncbi.nlm.nih.gov/PMC5520549 https://doaj.org/article/c78afea611ff471190a6edc70d36b9ab |
| Volume | 130 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3rb9MwELe2IR5fEK9B2ChGQkJIZG1etsO3bVo1IXWqBkPjU2Q7lzaoTUfbwdh_zH_BXV4s8I0vkRpfktq-x-_suzNjr2NAjJ2SpAWZdUMpjKtSrV1QBp0g33pWUL7z6EQcn4UfzqPzDRY1uTBl0L41-V4xm-8V-bSMrbyY234TJ9Yfjw6jyEekEfc32aYMgsZFr72sKJL1BqVwBcKfam8y9AZBv723RwmjAzq-yFdCRZLOo7yL6qaYfEOD0TFRZSX_f_X1DYP1dzDl7R-6yHQxuWGnhg_Y_Rpg8v2qIw_ZBhSP2J1RvYX-mP2q6hWv-CLjaKjSvFoM5HSQNqyAN5T84xQoMWzCv-BXrvKCH2r0qHFs-KLgxygga346_bmezrkuUj5E-0hv4kSIT1Hxju9Q0w11TtHvfFwVcV1xWv3lw2UZxr3mn6lPeRkQy8dLKiJLxKSpZnAFq_d8n5_iNxbz_BrSdxwxv5mBaxAg468yg5hGBZa8LnI6w46hWD1hZ8OjT4fHbn3eg2tx0tau8tPMylAEGXhqoPAq4iiTAF6gtDI6DbxQI-DQoD2IQAmcOADwYytlCrEKttlWsSjgGePGs1YEoQwjfCIWnrExOqoKvMgEBhGbw3ba6U4uqroeiZDEDR61vm0YoG1EZ4l4KCEeSoiHkoqHHHZAHNLSUbnu8sZiOUlqpk2sVDoDLTwvyxANIAjTAjlGDtJAmFgbh70k_kqq3NdW6ST7YawkgtIgctibkoLUDrKZ1XX2BHaXCnh1KHc7lKgubLe54eGkVlerBGF-hHKK0N1hr9pmepJC8ApYXBINjowQ6F447GnF8m2nGylymOwIQ2dUui0o22Ux81qWcQRqsfnzr66ndv7Vp4JOaGi85__97h12j95CK_L-YJdtrZeX8AKh5Nr0UIGcyx67dXB0Mj7tlQsyeB2Fqlcqld_HYXiW |
| link.rule.ids | 230,315,733,786,790,870,891,2115,2236,12083,21416,24346,27957,27958,31754,31755,33779,33780,43345,43840,53827,53829 |
| linkProvider | National Library of Medicine |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1tb9MwELagEy9fEO-EDWYkJIREWJ0Xx-EL6qZVBbZpGts0PkWOc2mL2mRrOxj7x_wL7hI3W0DiS6XG5yR2nrt7zi9nxl7HgBw7I03zc-MGkUxdlWntgkoxCPKMMJL2O-_uycFR8PkkPLEDbnO7rHJpEytDnZWGxsg3kImEeCtkFx9Pz1w6NYpmV-0RGjfZSuBjqNJhK5vbe_sHTcgVhpGdrZSuRC5UT1QGoutvNNfe0-7RbpVcYVQWwzN0GS0nVeXy_9diX3NZfy-nvPVTF7kuhtc8Vf8-u2cpJu_VmHjAbkDxkN3etZPoj9jvOmPxnJc5R1eVjevhQE5HacMc-FKSfx0BbQ0b8m_4lItxwbc0xtQTwJoFH6CKLPjB6NdiNOW6yHgfPSTdiZMg1qL0HT_AyvX1mNa_8_06jeuc0_gv78-qhdwLfkxtGldLYvn-jNLIkjDZqglcwPwD7_EDfEY5HV9C9o4j608n4KZIkfFftYeYegVm3KY5nWDDULEes6P-9uHWwLUnPrgGv9TCVV6WmyiQfg5CdRX-yjjMIwDhK61Snfki0Eg5NGgBISiEgwAALzZRlEGs_CesU5QFPGM8FcZIP4iCEGvEUqQmxlBVgQhTP0XO5rDV5nMnp3Vmj0RGnpJKUOnbJQCaQgyXCDgJASch4CQ1cBy2SQhp5Chhd3WhnA0Tq_-JiZTOQUsh8hz5ANIwLRExUTfzZRrr1GHrhK-k3v3amJ2kF8QqQlrqhw57U0mQ4UGYGW33T2BzKYVXS3KtJYkGw7SLlxhOrMGaJ1fq5bBXTTHVpEV4BZTnJIM9IyUGGA57WkO-aTT1G34Mz2FRSxlavdIuKcajKp15GHoYN8TYA1Ztrt7qcmSm3z1K6YSuRjz__4uvszuDw92dZOfT3pdVdpeq0SC8111jncXsHF4ge1ykL62J-AMejm-v |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Zb9QwELagiMIL9xFaqJGQEBLZ3VyOw1sprMrRalVoVXiJbGeyG9jNlt0USv8x_4KZXDTlrS8rbTx2Yuuby54ZM_YsArSxE-I0LzW2Hwpty0QpG6RGJ8g1jhGU77yzK7b3_feHweGZq77KoH2js14-nfXybFLGVh7NTL-JE-uPdraCwEVLI-ofJWn_MruCPOtGjaNe-1pBENbHlMIWaARVJ5S-M_D67bMepY0O6BIjVwoZhHQr5TUUOvn4B6qNjqIq6_n_L7XPqK3zIZVXf6k8Vfn4jLYa3mRfm3lWQSrfe8eF7pnTcyUgL7QQt9iN2oblmxXJbXYJ8jtsdac-pb_L_lQlkZd8nnLUhUlW7TdyuqsblsAbSv5pApR7NuZfcAonWc63FDrt-FY-z_k28mDB9ya_i8mMqzzhQ1TBNBInQuxF9UF-Qk03VBkF2PNRVSd2yWmDmQ8XZaR4wQ9owbIy5paPFlSnlohJGE7hBJav-Cbfw3fMZ9kpJC85uhV6CrZGGxz_lUnKtOSw4HUd1SlODDn3Htsfvv28tW3XV0rYBhFR2NJNUhP6wkvBkQOJvyIK0hDA8aSSWiWe4yu0aRQoBwKQAlEBAG5kwjCBSHr32Uo-z-Eh49oxRnh-6AfYIxKONhH6whKcQHsajUKLrbVYio-q0iGxCAlqDrW-aNDVNqI_RgCNCaAxATSuAGqx1wS_lo4qgpcP5otxXMMhNqFUKSjhOGmKBgfaeUogHMNB4gkdKW2xDQJvXKXXtnIt3vQjGaLd6wUWe15SkGRDDBtVJ2jgdKlGWIdyvUOJEsl0mxsGiWuJuIzRkwhQFKB3YLGnbTP1pCi_HObHRIMrIwR6MBZ7UPFTO-mGRS0WdjitsyrdFuSasl56zSW4AjVP_vuq04mZfXOpZhTqMufRhcfeYKujN8P447vdD2vsOg1I-__uYJ2tFItjeIyGa6GflCLqL-TkmLw |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Effects+of+Traditional+Chinese+Medicine+Shensong+Yangxin+Capsules+on+Heart+Rhythm+and+Function+in+Congestive+Heart+Failure+Patients+with+Frequent+Ventricular+Premature+Complexes%3A+A+Randomized%2C+Double-blind%2C+Multicenter+Clinical+Trial&rft.jtitle=Chinese+medical+journal&rft.au=Wang%2C+Xi&rft.au=Hu%2C+Dan&rft.au=Dang%2C+Song&rft.au=Huang%2C+He&rft.date=2017-07-20&rft.pub=Medknow+Publications+%26+Media+Pvt+Ltd&rft.issn=0366-6999&rft.volume=130&rft.issue=14&rft.spage=1639&rft.epage=1647&rft_id=info:doi/10.4103%2F0366-6999.209906&rft_id=info%3Apmid%2F28685712&rft.externalDBID=PMC5520549 |
| thumbnail_s | http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=http%3A%2F%2Fimage.cqvip.com%2Fvip1000%2Fqk%2F85656X%2F85656X.jpg http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=http%3A%2F%2Fwww.wanfangdata.com.cn%2Fimages%2FPeriodicalImages%2Fzhcmj%2Fzhcmj.jpg |